TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF THE EUROPE POINT OF CARE TESTING (POCT) MARKET 14
1.4 LIMITATIONS 15
1.5 MARKETS COVERED 15
2 EUROPE POINT OF CARE TESTING (POCT) MARKET: SEGMENTATION 17
2.1 MARKETS COVERED 17
2.2 GEOGRAPHICAL SCOPE 18
2.3 YEARS CONSIDERED FOR THE STUDY 18
2.4 CURRENCY AND PRICING 19
2.5 DBMR TRIPOD DATA VALIDATION MODEL 19
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 22
2.7 MULTIVARIATE MODELLING 23
2.8 PRODUCT LIFELINE CURVE 23
2.9 DBMR MARKET POSITION GRID 24
2.10 MARKET END USER COVERAGE GRID 25
2.11 SECONDARY SOURCES 26
2.12 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 29
4.1 PESTEL ANALYSIS 30
4.2 PORTER'S FIVE FORCES MODEL 31
5 MARKET OVERVIEW 32
5.1 DRIVERS 34
5.1.1 INCREASING PREVALENCE OF INFECTIOUS AND CHRONIC DISEASES 34
5.1.2 IMPROVED DIAGNOSIS-SEEKING RATE 34
5.1.3 DEMAND FOR WEARABLE OR PORTABLE GLUCOSE MONITORING DEVICES 35
5.1.4 RISING PREFERENCE FOR HOMECARE TESTING 35
5.2 RESTRAINTS 35
5.2.1 LACK OF ACCURACY 35
5.2.2 HIGH COST OF PRODUCT 36
5.2.3 LACK OF TRAINING 36
5.3 OPPORTUNITIES 36
5.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 36
5.3.2 RISING AWARENESS AND GOVERNMENT FUNDING 37
5.4 CHALLENGES 37
5.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES 37
5.4.2 IMPROPER CARE OF POCT DEVICES 37
6 EUROPE POINT OF CARE TESTING (POCT) MARKET, BY PRODUCT 38
6.1 OVERVIEW 39
6.2 INSTRUMENTS 42
6.2.1 MOBILE PLATFORM (SMALL) 43
6.2.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM) 43
6.3 CONSUMABLES & REAGENTS 43
6.4 OTHERS 43
7 EUROPE POINT OF CARE TESTING (POCT) MARKET, BY APPLICATION 44
7.1 OVERVIEW 45
7.2 BLOOD GLUCOSE 47
7.3 INFECTIOUS DISEASE TESTING 48
7.4 CARDIAC MONITORING 48
7.5 COAGULATION 48
7.6 WHOLE BLOOD ANALYSIS 49
7.7 CHOLESTEROL TESTING 49
7.8 VITAL SIGN MONITORING 49
7.9 URINE ANALYSIS 50
7.10 OTHERS 50
8 EUROPE POINT OF CARE TESTING (POCT) MARKET, BY END USER 51
8.1 OVERVIEW 52
8.2 LABORATORIES 55
8.3 HOSPITALS 55
8.4 CLINICS 55
8.5 HOMECARE 55
8.6 AMBULATORY CENTERS 56
8.7 ASSISTED LIVING FACILITIES 56
8.8 PHARMACIES/DRUG STORES 56
8.9 OTHERS 57
9 EUROPE POINT OF CARE TESTING (POCT) MARKET, BY MODE OF TESTING 58
9.1 OVERVIEW 59
9.2 PRESCRIPTION BASED TESTING 61
9.3 OTC TESTING 62
10 EUROPE POINT OF CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 63
10.1 OVERVIEW 64
10.2 THIRD PARTY DISTRIBUTOR 67
10.3 DIRECT SALES 67
10.4 ONLINE SALES 67
11 EUROPE POINT OF CARE TESTING (POCT) MARKET, BY COUNTRY 68
11.1 GERMANY 73
11.2 U.K. 75
11.3 FRANCE 77
11.4 SPAIN 79
11.5 ITALY 81
11.6 RUSSIA 83
11.7 NETHERLANDS 85
11.8 SWITZERLAND 87
11.9 TURKEY 89
11.10 BELGIUM 91
11.11 REST OF EUROPE 93
12 EUROPE POINT OF CARE TESTING (POCT) MARKET: COMPANY LANDSCAPE 94
12.1 COMPANY SHARE ANALYSIS: EUROPE 94
13 SWOT ANALYSIS 95
14 COMPANY PROFILE 96
14.1 F. HOFFMANN-LA ROCHE LTD 96
14.1.1 COMPANY SNAPSHOT 96
14.1.2 REVENUE ANALYSIS 96
14.1.3 PRODUCT PORTFOLIO 97
14.1.4 RECENT DEVELOPMENTS 97
14.2 SIEMENS HEALTHCARE GMBH 98
14.2.1 COMPANY SNAPSHOT 98
14.2.2 REVENUE ANALYSIS 98
14.2.3 PRODUCT PORTFOLIO 99
14.2.4 RECENT DEVELOPMENTS 100
14.3 WERFEN 101
14.3.1 COMPANY SNAPSHOT 101
14.3.2 PRODUCT PORTFOLIO 101
14.3.3 RECENT DEVELOPMENT 101
14.4 SYSMEX EUROPE SE. 102
14.4.1 COMPANY SNAPSHOT 102
14.4.2 REVENUE ANALYSIS 102
14.4.3 PRODUCT PORTFOLIO 103
14.4.4 RECENT DEVELOPMENTS 103
14.5 DANAHER 104
14.5.1 COMPANY SNAPSHOT 104
14.5.2 REVENUE ANALYSIS 104
14.5.3 PRODUCT PORTFOLIO 105
14.5.4 RECENT DEVELOPMENTS 105
14.6 QUIDEL CORPORATION 106
14.6.1 COMPANY SNAPSHOT 106
14.6.2 REVENUE ANALYSIS 106
14.6.3 PRODUCT PORTFOLIO 107
14.6.4 RECENT DEVELOPMENTS 107
14.7 LUMIRAXDX 108
14.7.1 COMPANY SNAPSHOT 108
14.7.2 REVENUE ANALYSIS 108
14.7.3 PRODUCT PORTFOLIO 109
14.7.4 RECENT DEVELOPMENTS 109
14.8 BD 110
14.8.1 COMPANY SNAPSHOT 110
14.8.2 REVENUE ANALYSIS 110
14.8.3 PRODUCT PORTFOLIO 111
14.8.4 RECENT DEVELOPMENTS 111
14.9 ABBOTT 112
14.9.1 COMPANY SNAPSHOT 112
14.9.2 REVENUE ANALYSIS 112
14.9.3 PRODUCT PORTFOLIO 113
14.9.4 RECENT DEVELOPMENTS 113
14.10 ABAXIS 114
14.10.1 COMPANY SNAPSHOT 114
14.10.2 PRODUCT PORTFOLIO 114
14.10.3 RECENT DEVELOPMENT 114
14.11 BINX HEALTH, INC. 115
14.11.1 COMPANY SNAPSHOT 115
14.11.2 PRODUCT PORTFOLIO 115
14.11.3 RECENT DEVELOPMENTS 115
14.12 CHEMBIO DIAGNOSTICS SYSTEMS, INC 116
14.12.1 COMPANY SNAPSHOT 116
14.12.2 REVENUE ANALYSIS 116
14.12.3 PRODUCT PORTFOLIO 117
14.12.4 RECENT DEVELOPMENTS 117
14.13 EKF DIAGNOSTICS 118
14.13.1 COMPANY SNAPSHOT 118
14.13.2 REVENUE ANALYSIS 118
14.13.3 PRODUCT PORTFOLIO 119
14.13.4 RECENT DEVELOPMENTS 119
14.14 NOVA BIOMEDICAL 120
14.14.1 COMPANY SNAPSHOT 120
14.14.2 PRODUCT PORTFOLIO 120
14.14.3 RECENT DEVELOPMENTS 121
14.15 PTS DIAGNOSTICS 122
14.15.1 COMPANY SNAPSHOT 122
14.15.2 PRODUCT PORTFOLIO 122
14.15.3 RECENT DEVELOPMENTS 123
14.16 SEKISUI DIAGNOSTICS 124
14.16.1 COMPANY SNAPSHOT 124
14.16.2 PRODUCT PORTFOLIO 124
14.16.3 RECENT DEVELOPMENT 125
14.17 TRINITY BIOTECH 126
14.17.1 COMPANY SNAPSHOT 126
14.17.2 REVENUE ANALYSIS 126
14.17.3 PRODUCT PORTFOLIO 127
14.17.4 RECENT DEVELOPMENTS 127
14.18 TRIVIDIA HEALTH, INC. 128
14.18.1 PRODUCT PORTFOLIO 128
14.18.2 RECENT DEVELOPMENT 128
14.19 THERMO FISHER SCIENTIFIC INC. (2021) 129
14.19.1 COMPANY SNAPSHOT 129
14.19.2 REVENUE ANALYSIS 129
14.19.3 PRODUCT PORTFOLIO 130
14.19.4 RECENT DEVELOPMENTS 130
14.20 QUANTUMDX GROUP LTD. 131
14.20.1 COMPANY SNAPSHOT 131
14.20.2 PRODUCT PORTFOLIO 131
14.20.3 RECENT DEVELOPMENT 131
15 QUESTIONNAIRE 132
16 RELATED REPORTS 135

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.